The U.S. FDA has granted accelerated approval to Eli Lilly's Retevmo (Selpercatinib) for pediatric patients two and older for thyroid cancer. The drug was already approved for patients 12 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback